
NG101 Antibody Clears Growth Barrier to Boost Spinal Cord Repair
In a multicenter phase 2b trial, NG101 neutralizes Nogo-A, enabling surviving and newly grown nerve fibers to regenerate around spinal lesions and reestablish connections with the spinal centers that control the limbs. MRI data show faster lesion reduction and preserved tissue, providing objective biomarkers for early treatment effects and suggesting potential gains in hand/arm function after acute cervical spinal cord injury, though full mobility restoration remains uncertain.













